A breast cancer patient who has enrolled in two clinical research trials at Vanderbilt-Ingram Cancer Center was the only presenter to receive a standing ovation during a recent Stand Up To Cancer (SU2C) news briefing at the American Association for Cancer Research (AACR) annual meeting in Chicago. Jeanette Daniel, 51, a metastatic breast cancer patient, […]
Combining targeted therapies might be required for maximum anti-tumor activity when treating HER2-positive breast cancers, according to two new studies by Vanderbilt-Ingram Cancer Center (VICC) investigators. The findings, reported in two papers in the Proceedings of the National Academy of Sciences (PNAS), suggest that upregulation of the HER3 receptor limits the effectiveness of two classes […]
A growing number of Hollywood celebrities, famous athletes and journalists will appear on the Stand Up To Cancer (SU2C) telecast on Friday, Sept. 10, at 7 p.m., to raise funds for cancer research. The one-hour live event will be simulcast commercial-free on ABC, NBC, CBS, FOX, HBO, Showtime, Discovery Health, E!, The Style Network, VH1 […]
At year-end, it is customary to review the accomplishments of the year that is ending and look with anticipation to the year ahead. By any measure, 2009 has been a year of remarkable progress for the Vanderbilt-Ingram Cancer Center.
Breast cancer researchers gathered earlier this month for the annual San Antonio Breast Cancer Symposium. In this video interview with the American Association for Cancer Research, you will hear Vanderbilt-Ingram Cancer Center’s Dr. Carlos Arteaga discuss translational insights for clinical research and practice at the meeting, as well as his exciting research in women’s cancer as part of a Stand Up To Cancer “Dream Team.”
William Pao, M.D., Ph.D., associate professor of Medicine, Vanderbilt-Ingram Cancer Center, has been awarded a grant from Stand Up to Cancer (SU2C) to study molecules that could speed up the search for new cancer drugs and targets. He is one of 13 young cancer investigators to earn a grant from SU2C.
Subscribe to our e-Newsletter to receive email updates: